Influx Healthtech IPO Upcoming
Already have an account? Apply now
Schedule of Influx Healthtech
| Issue open date | 18 Jun 2025 |
| Issue close date | 20 Jun 2025 |
| UPI mandate deadline | 20 Jun 2025 (5 PM) |
| Allotment finalization | 23 Jun 2025 |
| Refund initiation | 24 Jun 2025 |
| Share credit | 24 Jun 2025 |
| Listing date | 25 Jun 2025 |
| Mandate end date | 05 Jul 2025 |
| Lock-in end date for anchor investors (50%) | 23 Jul 2025 |
| Lock-in end date for anchor investors (remaining) | 21 Sep 2025 |
Note: The schedule is tentative. The anchor lock-in period ends 30 days after the actual allotment date for 50% of the shares and 90 days after for the remaining portion. The allotment status can be checked on the registrar's website and the exchange website.
About Influx Healthtech
Influx Healthtech is a Mumbai-based healthcare company specializing in contract development and manufacturing services (CDMO). Established in 2020, the company operates multiple manufacturing facilities in Thane, Maharashtra, with a combined area of over 36,000 square feet. These facilities hold certifications including GMP, HACCP, ISO 22000, and Halal, ensuring compliance with international quality and safety standards. Influx Healthtech offers manufacturing expertise across a broad range of products such as dietary and nutritional supplements, cosmetics, ayurvedic and herbal products, veterinary feed supplements, homecare products, active pharmaceutical ingredients (APIs), and finished dosage forms including tablets, capsules, and injectables.
Financials of Influx Healthtech
Issue size
| Funds Raised in the IPO | Amount |
| Overall | ₹58.57 crores |
| Fresh Issue | ₹48 crores |
| Offer for sale | ₹10.56 crores |
Utilisation of proceeds
| Purpose | INR crores (%) |
| Capital expenditure to set up manufacturing facility for Nutraceutical Division | 22.60 (47%) |
| Capital expenditure to set up manufacturing facility for Veterinary Food Division | 11.59 (24%) |
| Purchase of machineries for homecare and cosmetic division | 2.76 (5.75%) |
| General corporate purposes | 11.05 (23%) |
Strengths
- Diversified portfolio across nutraceuticals, Ayurveda, and wellness products reduces sector-specific risks.
- Rigorous QA/QC processes, global certifications (ISO, FDA), and adherence to food safety standards ensure consistent high product quality.
- Formulation team develops safe, stable, and custom nutraceutical, cosmetic, and veterinary products for clients.
Risks
- High reliance on the nutraceutical industry makes the company vulnerable to demand shifts or disruptions in that sector.
- Geographic concentration in Palghar, Maharashtra exposes the company to regional operational risks.
- Dependence on a few key customers (top 10 contributing ~47–50% of revenue) poses a risk, loss of any could significantly impact revenue and profitability.
- High dependence on top 10 suppliers (36–39%) without long-term contracts may disrupt operations if key relationships weaken or prices rise.
- Discrepancies and non-compliances in corporate records may lead to regulatory penalties, affecting the Company’s financial position.